Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 8/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | OTUD7B | Q6GQQ9 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4360871 | 1.00 | AVPR1A (0.54) | AVPR1ANPY5RSIGMAR1OTUD7B | |
| SCHEMBL3839594 | 0.82 | AVPR1A (0.60) | AVPR1ANPY5RSIGMAR1 | |
| SCHEMBL4048001 | 0.82 | SIGMAR1 (0.58) | AVPR1ANPY5RSIGMAR1 | |
| SCHEMBL31394077 | 0.77 | AVPR1A (0.51) | AVPR1ANPY5RSIGMAR1 | |
| SCHEMBL4372121 | 0.76 | NPY5R (0.46) | AVPR1ANPY5RSIGMAR1OTUD7B | |
| SCHEMBL3842297 | 0.76 | AVPR1A (0.50) | AVPR1ANPY5RSIGMAR1 | |
| SCHEMBL12488997 | 0.76 | SIGMAR1 (0.73) | AVPR1ASIGMAR1 | |
| SCHEMBL30281158 | 0.76 | SIGMAR1 (0.73) | AVPR1ASIGMAR1 | |
| SCHEMBL31394738 | 0.74 | AVPR1A (0.47) | AVPR1ANPY5RSIGMAR1 | |
| SCHEMBL30508369 | 0.72 | AVPR1A (0.48) | AVPR1ANPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2535329-A2 | Spiro-piperidine derivatives | F. Hoffmann-La Roche AG (CH) | 2012-12-19 | — | — | EP | disclosed |
| US-8084609-B2 | Vasopressin receptor (V1a) antagonists, treatment of anxiety and depressive disorders and other diseases | HOFFMAN-LA ROCHE INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084609-B2 | Vasopressin receptor (V1a) antagonists, treatment of anxiety and depressive disorders and other diseases | HOFFMAN-LA ROCHE INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084609-B2 | Vasopressin receptor (V1a) antagonists, treatment of anxiety and depressive disorders and other diseases | HOFFMAN-LA ROCHE INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-7629353-B2 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as V1a receptor antagonists | HOFFMAN-LA ROCHE INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629353-B2 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as V1a receptor antagonists | HOFFMAN-LA ROCHE INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629353-B2 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as V1a receptor antagonists | HOFFMAN-LA ROCHE INC. (US) | 2009-12-08 | — | — | US | disclosed |
| EP-2097376-A2 | SPIRO-PIPERIDINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-09-09 | — | — | EP | disclosed |
| EP-1904477-B1 | INDOL-3-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2009-01-21 | — | — | EP | disclosed |
| EP-1904477-B1 | INDOL-3-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2009-01-21 | — | — | EP | disclosed |
| US-20080153862-A1 | SPIROPIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080153861-A1 | SPIROPIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080146557-A1 | INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS VIa RECEPTOR ANTAGONISTS | BISSANTZ CATERINA | 2008-06-19 | — | — | US | disclosed |
| US-20080146557-A1 | INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS VIa RECEPTOR ANTAGONISTS | BISSANTZ CATERINA | 2008-06-19 | — | — | US | disclosed |
| US-20080146557-A1 | INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS VIa RECEPTOR ANTAGONISTS | BISSANTZ CATERINA | 2008-06-19 | — | — | US | disclosed |
| US-7332501-B2 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as V1a receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332501-B2 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as V1a receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070027173-A1 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-01 | — | — | US | disclosed |
| US-20070027173-A1 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-01 | — | — | US | disclosed |
| WO-2007006688-A1 | INDOL-3-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153861-A1 | SPIROPIPERIDINE DERIVATIVES | AVPR1A, AVPR1B, AVPR2 | AVPR1A 1/4885NPY5R 22/4885SIGMAR1 57/4885 |
| US-20070027173-A1 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists | AVPR1A, AVPR2, AVPR1B | AVPR1A 1/4885NPY5R 200/4885SIGMAR1 44/4885 |
| US-20080153862-A1 | SPIROPIPERIDINE DERIVATIVES | AVPR1A, AVPR1B, AVPR2 | AVPR1A 1/4885NPY5R 22/4885SIGMAR1 57/4885 |
| US-20080146557-A1 | INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS VIa RECEPTOR ANTAGONISTS | AVPR1A, AVPR2, OXTR | AVPR1A 1/4885NPY5R 79/4885SIGMAR1 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.